Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991346 | 0.87 | ALDH1A1 (0.49) | MAPTALDH1A1SMN1; SMN2KMT2AHPGD | |
| SCHEMBL21991561 | 0.86 | KDM4E (0.45) | MAPTALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL21991973 | 0.86 | MAPT (0.44) | MAPTALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL21991336 | 0.84 | CYP1A2 (0.50) | ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL21991567 | 0.84 | TSHR (0.43) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL21992712 | 0.84 | KDM4E (0.54) | MAPTALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL7749771 | 0.84 | MAPT (0.51) | MAPTALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL19027641 | 0.81 | ALDH1A1 (0.51) | MAPTALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL19027644 | 0.81 | ALDH1A1 (0.51) | MAPTALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL21991581 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAPT 4264/4885ALDH1A1 932/4885KDM4E 4518/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | MAPT 4264/4885ALDH1A1 932/4885KDM4E 4518/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAPT 4264/4885ALDH1A1 932/4885KDM4E 4518/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MAPT 4264/4885ALDH1A1 932/4885KDM4E 4518/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MAPT 4264/4885ALDH1A1 932/4885KDM4E 4518/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAPT 4264/4885ALDH1A1 932/4885KDM4E 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.